A multicentre, Phase II, open-label, randomized study in previously untreated patients with advanced indolent non-hodgkin's lymphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with Rituximab plus chemotherapy followed by GA101 or Rituximab maintenance therapy in responders BO21223